OncLive Staff

Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.

Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.

The FDA has granted breakthrough device designation to Merlin CP-GEP, a clinicopathologic gene expression profile test for stratifying risk in early-stage cutaneous melanoma.

Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.

Epcoritamab plus lenalidomide reduced the risk of disease progression or death vs R-GemOx in relapsed/refractory DLBCL in the EPCORE DLBCL-4 trial.

Elisrasib produced a 58.8% ORR and 12.2-month median PFS in KRAS G12C inhibitor–naive NSCLC and remained active in G12C inhibitor–refractory disease.

Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.

SB27, a proposed pembrolizumab biosimilar, met primary end points in phase 1 pharmacokinetic and a phase 3 efficacy studies.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.

The enzalutamide bioequivalent received tentative FDA approval, pending patent expiry on branded Xtandi before final marketing authorization.

IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.

Translational profiling tied CCR4 loss, IL enrichment, and BCL-2 upregulation to mogamulizumab resistance; venetoclax may be a combination partner.

In a phase 1 trial, duvelisib plus nivolumab produced a 26% overall response rate in relapsed/refractory cutaneous T-cell lymphoma but was limited by immune-mediated toxicities.

Real-world mogamulizumab reduced skin symptoms and improved health-related quality of life in patients with mycosis fungoides and Sézary syndrome.

CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.

The final analysis of the Italian FIL-MOGA study showed an objective response lasting at least 4 months in 47% of patients and identified the measure as a surrogate for survival outcomes.

Distinct somatic mutation profiles separated responders from non-responders to mogamulizumab in mycosis fungoides and Sézary syndrome.

Daratumumab-based retreatment remained active in a broadly inclusive, transplant-ineligible newly diagnosed multiple myeloma population.

An off-the-shelf BCMA-directed CAR T-cell therapy generated a 100% overall response rate and universal MRD negativity in heavily pretreated myeloma.

Maintenance with chidamide and azacitidine generated high 3-year overall survival and a low relapse incidence in high-risk AML after allogeneic transplant.

In a phase 2 study, adding venetoclax to ibrutinib rendered BTK C481X resistance mutations undetectable in patients with CLL.

Both the reactive and proactive ibrutinib dose-adjustment cohorts of the phase 2 TAILOR study met the primary ORR end point in previously untreated CLL.

The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.

Six-year GARNET data show durable responses with dostarlimab in dMMR/MSI-H endometrial cancer.

The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The CDK4/6 inhibitor and aromatase inhibitor combination produced a 32% ORR and 48% clinical benefit rate at 6 months.

Updated data from the phase 2 COLIBRI-1 trial suggest that immune microenvironment status at baseline and following ICB induction may predict long-term survival.

Trastuzumab pamirtecan produced durable responses and encouraging survival in HER2-expressing endometrial cancer after prior therapy.